CAFs-derived insulin-like growth factor-II (IGF-II) can activate IGF-II/IGF1 receptor/Nanog signaling to maintain CSCs, which is related to poor prognosis in lung cancer patients [75]. The gene discussed is IGF2; the disease is lung carcinoma.